EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
作者： Florent Baty , Sacha Rothschild , Martin Früh , Daniel Betticher , Cornelia Dröge
DOI: 10.1371/JOURNAL.PONE.0072966
关键词:
摘要: Activating epidermal growth factor receptor (EGFR) mutations are recognized biomarkers for patients with metastatic non-small cell lung cancer (NSCLC) treated EGFR tyrosine kinase inhibitors (TKIs). TKIs can also have activity against NSCLC without mutations, requiring the identification of additional relevant biomarkers. Previous studies on tumor protein levels and gene copy number revealed inconsistent results. The aim study was to identify novel response in by investigating whole genome expression at exon-level. We used exon arrays clinical samples from a previous trial (SAKK19/05) investigate variations exon-level 3 genes potentially playing key role modulating treatment response: EGFR, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) vascular endothelial (VEGFA). identified 18 as new predictive marker untreated bevacizumab erlotinib first line setting. overexpression significantly associated shrinkage, independently mutation status. A similar significant association could be found blood samples. In conclusion, exonic particularly biomarker erlotinib. Based these results, we propose model testing blood.
core.ac.uk
harvard.edu
sci-hub.st 参考文章(49)
M. G. Kris, B. E. Johnson, D. J. Kwiatkowski, A. J. Iafrate, I. I. Wistuba, S. L. Aronson, J. A. Engelman, Y. Shyr, F. R. Khuri, C. M. Rudin, E. B. Garon, W. Pao, J. H. Schiller, E. B. Haura, K. Shirai, G. Giaccone, L. D. Berry, K. Kugler, J. D. Minna, P. A. Bunn, Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). Journal of Clinical Oncology. ,vol. 29, ,(2011) , 10.1200/JCO.2011.29.15_SUPPL.CRA7506
M.W. Pedersen, M. Meltorn, L. Damstrup, H.S. Poulsen, The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy Annals of Oncology. ,vol. 12, pp. 745- 760 ,(2001) , 10.1023/A:1011177318162
F. F. Kabbinavar, V. A. Miller, B. E. Johnson, P. G. O'Connor, C. Soh, , Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. ,vol. 28, pp. 7526- 7526 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.7526
Jill L. Reiter, David W. Threadgill, Greg D. Eley, Karen E. Strunk, Andrew J. Danielsen, Colleen Schehl Sinclair, R.Scott Pearsall, Patricia J. Green, Della Yee, Andrea L. Lampland, Swarna Balasubramaniam, Tonia D. Crossley, Terry R. Magnuson, C.David James, Nita J. Maihle, Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics. ,vol. 71, pp. 1- 20 ,(2001) , 10.1006/GENO.2000.6341
Naoki Hijiya, Michiyo Miyawaki, Katsunobu Kawahara, Shinji Akamine, Koh-ichi Tsuji, Jun-ichi Kadota, Shin'ichiro Akizuki, Tomohisa Uchida, Keiko Matsuura, Yoshiyuki Tsukamoto, Masatsugu Moriyama, Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma Human Pathology. ,vol. 39, pp. 316- 323 ,(2008) , 10.1016/J.HUMPATH.2007.10.027
Tommaso De Pas, Francesca Toffalorio, Michela Manzotti, Caterina Fumagalli, Gianluca Spitaleri, Chiara Catania, Angelo Delmonte, Monica Giovannini, Lorenzo Spaggiari, Filippo de Braud, Massimo Barberis, Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations Journal of Thoracic Oncology. ,vol. 6, pp. 1895- 1901 ,(2011) , 10.1097/JTO.0B013E318227E8C6
Isamu Okamoto, Lawrence C. Kenyon, David R. Emlet, Takeshi Mori, Ji-ichiro Sasaki, Susumu Hirosako, Yasuko Ichikawa, Hiroto Kishi, Andrew K. Godwin, Masakazu Yoshioka, Moritaka Suga, Mitsuhiro Matsumoto, Albert J. Wong, Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Science. ,vol. 94, pp. 50- 56 ,(2003) , 10.1111/J.1349-7006.2003.TB01351.X
Shuji Ichihara, Shinichi Toyooka, Yoshiro Fujiwara, Katsuyuki Hotta, Hisayuki Shigematsu, Masaki Tokumo, Junichi Soh, Hiroaki Asano, Kouichi Ichimura, Keisuke Aoe, Motoi Aoe, Katsuyuki Kiura, Kenji Shimizu, Hiroshi Date, Nobuyoshi Shimizu, The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer International Journal of Cancer. ,vol. 120, pp. 1239- 1247 ,(2007) , 10.1002/IJC.22513
Jill L. Reiter, David W. Threadgill, Greg D. Eley, Karen E. Strunk, Andrew J. Danielsen, Colleen Schehl Sinclair, R. Scott Pearsall, Patricia J. Green, Della Yee, Andrea L. Lampland, Swarna Balasubramaniam, Tonia D. Crossley, Terry R. Magnuson, C. David James, Nita J. Maihle, Erratum to Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms [Genomics, 71, (2001), 1-20] Genomics. ,vol. 96, pp. 128- ,(2010) , 10.1016/J.YGENO.2010.05.004
Jeffrey A Engelman, Toru Mukohara, Kreshnik Zejnullahu, Eugene Lifshits, Ana M Borrás, Christopher-Michael Gale, George N Naumov, Beow Y Yeap, Emily Jarrell, Jason Sun, Sean Tracy, Xiaojun Zhao, John V Heymach, Bruce E Johnson, Lewis C Cantley, Pasi A Jänne, None, Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer Journal of Clinical Investigation. ,vol. 116, pp. 2695- 2706 ,(2006) , 10.1172/JCI28656